2,420 results match your criteria: "European Institute of Oncology - IRCCS[Affiliation]"

Background: Some evidence suggests that fluid resuscitation with lactated Ringer's solution (LR) may have an anti-inflammatory effect on acute pancreatitis (AP) when compared to normal saline (NS) and may be associated with a decrease in severity, but existing single-center randomized controlled trials showed conflicting results. The WATERLAND trial aims to investigate the efficacy and safety of fluid resuscitation using LR compared to NS in patients with AP.

Methods: The WATERLAND trial is an international multicenter, open-label, parallel-group, randomized, controlled, superiority trial.

View Article and Find Full Text PDF
Article Synopsis
  • Burkitt lymphoma (BL) is a common type of B-cell lymphoma in kids, with many being cured but some showing resistance to treatment.
  • Researchers used single-cell transcriptomics to study the differences between patients who respond to therapy and those who don’t, finding that non-responders have more immune cells and a specific gene, Tropomyosin 2 (TPM2), highly expressed in their tumors.
  • The study suggests that the level of TPM2 can help predict treatment outcomes for BL patients, highlighting the disease's genetic diversity and potential biomarkers for therapy resistance.
View Article and Find Full Text PDF

Objectives: This meta-analysis compares the efficacy, limitations, and clinical implications of abbreviated breast MRI (AB-MRI) and full protocol MRI (FP-MRI), focusing on diagnostic accuracy across diverse populations. It extends previous analyses by including studies conducted after 2019 in both screening and diagnostic contexts.

Methods: We conducted a systematic review (November 2019 to December 2022), using a bivariate model to calculate summary estimates of sensitivity and specificity.

View Article and Find Full Text PDF
Article Synopsis
  • The review examines how online medical resources and AI tools are changing radiation oncology practices by enhancing clinical decision-making.* -
  • A search of several databases identified 70 relevant studies that demonstrate the integration of web-based tools in various aspects of radiation therapy, including calculations and educational needs.* -
  • The findings indicate that these digital tools can improve personalized cancer treatment strategies, particularly across different cancer types, with a focus on breast and head & neck cancers.*
View Article and Find Full Text PDF
Article Synopsis
  • This paper presents guidelines from major Italian medical associations on the use of radioligand therapy (RLT) for treating neuroendocrine neoplasms (NENs).
  • It addresses 10 key questions regarding RLT’s effectiveness in treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs) based on literature review and expert opinions.
  • The focus is on well-differentiated GEP-NETs that express somatostatin receptors, identifying which patients are appropriate candidates for RLT according to established international protocols.
View Article and Find Full Text PDF
Article Synopsis
  • Innovations in advanced prostate cancer have improved outcomes, but there's still a lack of high-level evidence in clinical management, prompting the 2024 Advanced Prostate Cancer Consensus Conference to survey experts for insights.
  • A panel of 120 international experts developed and voted on 183 consensus questions through a web-based survey prior to the conference, defining consensus as ≥75% agreement.
  • The voting results highlight areas of agreement and disagreement that can guide clinical decisions and future research, with a focus on individualizing treatment based on patient characteristics and encouraging participation in clinical trials.
View Article and Find Full Text PDF
Article Synopsis
  • - In the KEYNOTE-826 study, pembrolizumab combined with chemotherapy significantly boosted overall survival (OS) and progression-free survival (PFS) in patients with advanced cervical cancer, with specific attention to those using bevacizumab.
  • - The analysis included 617 patients, with a majority excluded from bevacizumab due to medical reasons; outcomes showed that those receiving pembrolizumab generally had better survival metrics, regardless of bevacizumab use.
  • - Patients on pembrolizumab experienced a high rate of severe side effects, with 74% suffering grade ≥3 treatment-related adverse events in the bevacizumab group.
View Article and Find Full Text PDF

Background: The aim was to evaluate the performance of the Peritoneal Cancer Index (PCI) using imaging (ultrasound, contrast-enhanced computed tomography (CT), and whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) in assessing peritoneal carcinomatosis and predicting non-resectability in tubo-ovarian carcinoma patients.

Methods: This was a prospective multicenter observational study. We considered all patients with suspected primary ovarian/tubal/peritoneal cancer who underwent preoperative ultrasound, CT, and WB-DWI/MRI (if available).

View Article and Find Full Text PDF

Introduction: Several studies have demonstrated that, following a breast cancer (BC) diagnosis, patients are eager to obtain information on cancer and nutrition, in order to ameliorate both their quality of life (QoL) and disease outcome. To avoid BC survivors to get wrong information from unreliable sources, healthcare providers need to be aware of patients' needs, to guide them toward optimal nutrition recommendations, aimed at preventing tumor recurrence and increasing survival rates.

Material And Methods: The cross-sectional web-based survey "Nutrition and breast cancer, what would you like to know?" has been conceived and conducted, in Italy, between the 2nd and the 25th of June 2023.

View Article and Find Full Text PDF
Article Synopsis
  • The study addresses the advancement of synthetic CT (sCT) in MR-guided radiotherapy and aims to define current practices through a survey distributed among ESTRO members in 2023.
  • Results showed that sCT is primarily used for pelvic treatments and conventional fractionation, with varying application across different areas and limited engagement in proton therapy.
  • A strong consensus emerged for the need for standardized, vendor-neutral guidelines to improve the development and use of sCT in clinical settings, as many centers lack dedicated quality assurance programs.
View Article and Find Full Text PDF
Article Synopsis
  • The PERLA study compared the effectiveness and safety of two treatments—dostarlimab (DCT) and pembrolizumab (PCT)—alongside chemotherapy for patients with advanced non-small cell lung cancer.
  • An exploratory analysis collected patient-reported outcomes (PROs) through various assessments over the treatment duration, with a focus on health-related quality of life.
  • Results indicated that both treatments provided similar levels of quality of life, but DCT showed advantages in reducing dyspnea and chest pain, making it a viable option for future therapies.
View Article and Find Full Text PDF
Article Synopsis
  • - The Italian Lung Cancer Observational Study (LUCENT) focuses on improving understanding and treatment of non-small cell lung cancer (NSCLC) by analyzing patient outcomes in Italy, particularly for those with early and locally advanced cases.
  • - The study will use a web-based registry to collect real-world data on surgical, oncological, and socioeconomic factors, aiming to inform healthcare decisions and establish national benchmarks for NSCLC treatments.
  • - By evaluating both clinical and psychosocial impacts, LUCENT addresses gaps in current knowledge and aims to enhance understanding of patient experiences, with recruitment planned from January 2024 to December 2026.
View Article and Find Full Text PDF

Third-generation EGFR tyrosine kinase inhibitor (TKIs) have revolutionized the treatment landscape for patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations, with improved long-term outcomes compared to first-generation TKIs. Nevertheless, disease progression inevitably occurs, limiting osimertinib long-term efficacy. Indeed, the molecular biology underlying acquired resistance to first-line osimertinib is multifaceted and includes the emergence of on-target and off-target alterations.

View Article and Find Full Text PDF

Objective: Textbook oncologic outcome (TOO) has been validated in surgical oncology as a composite quality measure correlated with oncologic outcomes. We aimed to assess the association between TOO and overall survival (OS) in patients undergoing primary treatment for advanced epithelial tubo-ovarian cancer (AEOC).

Methods: Patients undergoing surgery for AEOC between 2008 and 2019 were identified in the National Cancer Database (NCDB).

View Article and Find Full Text PDF

To understand how oncogenes affect genome organization, it is essential to visualize fundamental processes such as DNA replication and transcription at high resolution in intact cells. At the same time, it is important to determine the progression of the cell along the cell cycle, as cell cycle regulation is crucial for the control of cell proliferation and oncogenesis. Here, we present a super-resolution imaging-based method to analyze single cell nuclei sorted according to specific phases of the cell cycle.

View Article and Find Full Text PDF

We evaluated response to VEN/HMA in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease (EMD). Median age was 65 (range, 19-81) years. Patients had a median of two EMD sites (range, 1-5) and 35 (76%) patients had concurrent bone marrow involvement.

View Article and Find Full Text PDF

Introduction: Novel compounds have entered the triple-negative breast cancer (TNBC) treatment algorithm, namely immune checkpoints inhibitors (ICIs), PARP inhibitors and antibody-drug conjugates (ADCs). The optimization of treatment efficacy can be enhanced with the use of combination treatments, and the incorporation of novel compounds. In this review, we discuss the combination treatments under development for the treatment of TNBC.

View Article and Find Full Text PDF

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.

ESMO Open

October 2024

Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan. Electronic address:

Background: Somatic genetic alterations of the estrogen receptor 1 gene (ESR1) are enriched in endocrine therapy-resistant, estrogen receptor-positive (ER+) metastatic breast cancer (mBC). Herein, we investigated and compared the clinical and genomic landscape of ESR1-mutant (ESR1) and ESR1 wild type (ESR1) ER+/ human epidermal growth factor receptor 2 (HER2)- mBCs.

Methods: Clinical and genomic data were retrieved from cBioPortal using the publicly-available MSK MetTropism dataset.

View Article and Find Full Text PDF

Monkeypox: a new threat for healthcare and urology?

Arch Ital Urol Androl

October 2024

Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genoa.

Article Synopsis
  • Monkeypox is a viral disease caused by the Monkeypox virus, which starts in animals and can spread to humans.
  • Historically, it was mostly found in central and west Africa, but it has recently expanded to multiple regions around the world.
  • This spread has raised significant concerns for global health authorities as they work to manage and contain the virus.
View Article and Find Full Text PDF
Article Synopsis
  • - Enfortumab vedotin (EV) is effective for patients with advanced urothelial carcinoma who have previously received platinum chemotherapy and immune therapy, despite lacking research on those treated with avelumab maintenance.
  • - A study of 182 patients showed a median overall survival of 12.7 months and a progression-free survival of 7.9 months, with 39% achieving a positive response to EV after avelumab treatment.
  • - The study confirms EV's effectiveness, suggesting it can be a viable option for patients previously treated with avelumab, with manageable side effects like grade ≥ 3 neuropathy and skin rash occurring in a minority of cases.
View Article and Find Full Text PDF
Article Synopsis
  • Radiopharmaceutical theranostic treatments are becoming increasingly popular for cancer therapy, especially for CNS tumors, and rely on the internal release of radiation to achieve clinical effects.
  • Accurate absorbed dose calculations are crucial for understanding how the treatment works and customizing it for individual patients.
  • The article emphasizes the advancements in internal dosimetry techniques, the importance of consistent data collection for treatment planning, and the challenges faced in applying these methods effectively.
View Article and Find Full Text PDF

Background: The use of inpatient palliative care (IPC) in advanced cancer patients represents a well-established guideline recommendation. This study examines the utilization rates and patterns of IPC among patients with metastatic adrenocortical carcinoma (mACC).

Methods: Relying on the Nationwide Inpatient Sample database (2007-2019), we tabulated IPC rates in mACC patients.

View Article and Find Full Text PDF